Concepedia

Sreeraj Macha

SM

Statistics

Publications

45

Citations

2K

H-Index

25

Active since

2001

Affiliations

Boehringer Ingelheim (Germany)(Current)

Boehringer Ingelheim (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Profil Institute for Metabolic Research

University of Missouri–Kansas City

Sreeraj Macha is an author at Boehringer Ingelheim (Germany) specializing in pharmacology, clinical pharmacology, and pharmacokinetics.

Publications per year

2001–2021

45

Publications

45

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Tim Heise, Elke Seewaldt-Becker, Sreeraj Macha et al. · Diabetes Obesity and Metabolism · 2013 · 271 citations

, , +15

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

Leo Seman, Sreeraj Macha, Gerhard Nehmiz et al. · Clinical Pharmacology in Drug Development · 2013 · 137 citations

, , +11

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Tim Heise, Leo Seman, Sreeraj Macha et al. · Diabetes Therapy · 2013 · 126 citations · Full text

, , +17

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, in subjects with renal impairment

Sreeraj Macha, Michaela Mattheus, Atef Halabi et al. · Diabetes Obesity and Metabolism · 2013 · 111 citations

, , +17

The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus

Jens Jordan, Jens Tank, Karsten Heusser et al. · Journal of the American Society of Hypertension · 2017 · 97 citations

, , +8

1–5 of 45